文献速递免疫规划传染病防控与疫情报告

异源与同源mRNA新冠疫苗接种后的抗体水平相当,但同源mRNA加强免疫的中和抗体与IgA抗体应答更优

Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
PubMed 文献 · Vaccine · 2024-06-05

研究纳入1113名受试者,包括895名不同接种策略的未感染者和218名未接种的自然感染者,比较同源与异源加强免疫的抗体应答。结果显示两种加强方案的总抗体和抗S-RBD IgG水平无显著差异,但同源mRNA加强在提升中和总抗体和抗S1 IgA水平上显著优于异源加强,其中BNT/BNT/BNT方案提升尤为明显(p < 0.05)。

要点

  • mRNA疫苗基础免疫的免疫原性优于ChAd疫苗,mRNA-1273显著提升中和总抗体、总抗体、抗S-RBD IgG和抗S1 IgA水平(p < 0.001)。
  • 同源与异源加强均能提升抗体水平,但两者在总抗体和抗S-RBD IgG水平上无显著差异。
  • 同源mRNA加强在提升中和总抗体和抗S1 IgA水平上显著优于异源加强,BNT/BNT/BNT方案提升更高(p < 0.05)。

核心结论

  • 尽管两种加强方案的总抗体和抗S-RBD IgG抗体水平相似,但同源mRNA加强通过提升抗S1 IgA和中和抗体水平优于异源方案。

研究设计与样本

  • 研究检测了1113名受试者的抗体应答,包括895名采用不同接种策略(部分接种、基础免疫、异源加强、同源加强)的疫苗未感染者及218名未接种的自然感染者。

主要发现

  • mRNA疫苗基础免疫的免疫原性优于ChAd,mRNA-1273显著提升中和总抗体、总抗体、抗S-RBD IgG和抗S1 IgA水平(p < 0.001)。
  • 两种加强类型均使抗体水平超过基础免疫后水平,且方案间的总抗体和抗S-RBD IgG水平无显著差异。
  • 同源mRNA加强在提升中和总抗体和抗S1 IgA水平上显著优于异源加强,BNT/BNT/BNT方案提升尤为明显(p < 0.05)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Priming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. AIM: To evaluate and contrast the immunogenicity of homologous and heterologous boosting regimens. METHOD: The study examined antibody responses in 1113 subjects, comprising 895 vaccine-naïve individuals across different vaccination strategies (partial, primary series, heterologous booster, homologous booster) and 218 unvaccinated, naturally infected individuals. Assessments included neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA levels. RESULTS: The study found mRNA vaccines to exhibit superior immunogenicity in primary series vaccination compared to ChAd, with mRNA-1273 significantly enhancing NTAbs, TAbs, anti-S-RBD IgG, and anti-S1 IgA levels (p < 0.001). Both booster types improved antibody levels beyond primary outcomes, with no significant difference in TAbs and anti-S-RBD IgG levels between regimens. However, homologous mRNA boosters significantly outperformed heterologous boosters in enhancing NTAbs and anti-S1 IgA levels, with the BNT/BNT/BNT regimen yielding particularly higher enhancements (p < 0.05). CONCLUSION: The study concludes that although TAbs and anti-S-RBD IgG antibody levels are similar for both regimens, homologous mRNA boosting outperform heterologous regimen by enhancing anti-S1 IgA and neutralizing antibody levels.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Younes S, Nicolai E, Younes N, et al. Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting. Vaccine. 2024. PMID: 38845303. doi:10.1016/j.vaccine.2024.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。